BioSecBench-Surveillance: A Verifiable Benchmark for AI Agents in Pathogen Genomic Surveillance
Abstract
As pathogen genomic surveillance scales, the bottleneck is shifting from data generation to analysis.
We present BioSecBench-Surveillance, a verifiable benchmark of 100 evaluations testing whether AI agents can infer the right analysis pipeline from raw sequencing data and surveillance context.
Each evaluation gives an agent only the data and context a human analyst would have, then grades its structured answer deterministically.
The tasks span seven categories, from taxonomic classification to genetic-engineering detection, across diverse sample types and sequencing technologies.
Across 3,962 gradable attempts from sixteen model-harness pairs, the strongest configuration cleared only about half.
Opus 4.8 with PI led at 50.2 percent, with a 95 percent confidence interval of 40.1 to 60.3 percent across 83 evaluations, tied with GPT-5.5 with Codex at 50.2 percent, with a 95 percent confidence interval of 40.8 to 59.6 percent, followed by Opus 4.7 with PI at 49.6 percent, with a 95 percent confidence interval of 40.0 to 59.2 percent, and Sonnet 4.6 with PI at 48.6 percent, with a 95 percent confidence interval of 38.9 to 58.3 percent.
Even when agents invoked the correct workflows, their mistakes came from the choices around them, such as which references, thresholds, filters, and normalization to apply.
BioSecBench-Surveillance provides a standard for measuring whether agents can be trusted to perform genomic surveillance when the next outbreak arrives.
이 뉴스, 어떠셨어요?
탭 한 번으로 반응 · 로그인 불필요
공식 발표 ↔ 진영별 보도
Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submission
보도 없음
보도 없음
보도 없음